The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China

Not yet recruitingOBSERVATIONAL
Enrollment

800

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

May 10, 2025

Study Completion Date

September 30, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
OTHER

Patient-reported outcome

"Patient-reported outcome data will be collected using the following instruments:EORTC QLQ-C30, EORTC QLQ-LC13, selected items from the PRO-CTCAE, EORTC-IL46.~The first collection of the information in questionnaires (EORTC QLQ-C30, EORTC QLQ-LC13, PRO-CTCAE \[select items\]), which defined as baseline- PROs, will be completed at Cycle 1, Day 1±7days prior to administration of study drug; then the rest times of collection will be completed at every two treatment cycle prior to administration of study drug (i.e., on Cycle 3, Day 1±7days; Cycle 5, Day 1±7days; Cycle 7, Day 1±7days; Cycle 9, Day 1±7days; Cycle 11, Day 1±7days; Cycle 13, Day 1±7days) . EORTC-IL46 will be completed at Cycle 3, Day 1±7days (baseline) prior to administration of study drug; then at every other study treatment cycle prior to administration of study drug (i.e., on Cycle 5, Day 1±7days; Cycle 7, Day 1±7days; Cycle 9, Day 1±7days; Cycle 11, Day 1±7days; Cycle 13, Day 1±7days)"

All Listed Sponsors
collaborator

Zhejiang Cancer Hospital

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

lead

Shanghai East Hospital

OTHER

NCT06586801 - The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China | Biotech Hunter | Biotech Hunter